Jefferson Establishes Vaccine Center
(Published: 10-26-2007) After decades of pioneering research in fields ranging from melanoma and colon cancer to HIV and rabies,
vaccine researchers at Thomas Jefferson University finally have a “home” to call their own. Jefferson has established the
Jefferson Vaccine Center to create an infrastructure for all of the university’s research and clinical efforts, while hoping
to spur new collaboration and innovation.
JAMA Editorial: Jefferson Pharmacologist Says Biomarker Discovery Bodes Well for Better Cancer Diagnostics, Personalized Medicine
(Published: 5-1-2007)While new findings from Ohio State University scientists suggest a genetic marker that could help distinguish
between chronic pancreatitis and pancreatic cancer and gauge who will do well with cancer treatment, a pharmacologist at the
Kimmel Cancer Center at Jefferson in Philadelphia sees the discovery as much more.
New Chief Financial Officer Joins the Kimmel Cancer Center at Thomas Jefferson University
(Published: 10-9-2006) Richard W. Haldeman, MBA, has joined the Kimmel Cancer Center (KCC) at Thomas Jefferson University
in Philadelphia as its new Chief Financial Officer (CFO). In this new position, Mr. Haldeman will financially integrate the
research and clinical functions of the organization. He will also serve as lead financial representative for KCC director
Richard G. Pestell, M.D., Ph.D., in both of his roles as Vice President of Oncology Services at Thomas Jefferson University
Hospital and Associate Dean for Cancer Programs at Thomas Jefferson University.
Noted Cell Biologist Michael P. Lisanti, M.D., Ph.D., Brings Wide-Ranging Expertise to Kimmel Cancer Center at Jefferson
(Published: 05-5-2006) 15th most frequently cited in biochemistry and biology in the last decade.
Featured in the Media
Colleges Make Own Medicine to Ease Research
(Published 5-5-06, The Philadelphia Inquirer) Across the country, universities are beginning to manufacture drugs in their
own facilities. These universities offer lower-cost drugs and placebos, hoping to spark more “off-label” studies.
Conducting more studies allows researchers to investigate claims about alternative medicines and encourages independently
created products. Funding for these studies is an issue for some researchers. However, Scott Waldman, M.D., Ph.D., chair of
the department of Pharmacology and Experimental Therapeutics at Jefferson Medical College says that his studies have always
been funded from outside sources. For individual investigators, Dr. Waldman feels, “Having the availability to go to a place
like this and say, ‘Here’s the study I’m trying to do,’ it would be available resource.”
Media Coverage:
The Philadelphia Inquirer
Times Leader
Philadelphia Daily News
The Kansas City Star
Contra Costa Times
Charlotte Observer
The State
Jefferson Scientists Reveal New Mechanism That Causes Spread of Colorectal Cancer(Published 3-31-06) Researchers have known for years that the enzyme MMP-9 plays a key role in the spread of colorectal cancer.
Now, scientists at Jefferson Medical College in Philadelphia have found out how the enzyme helps initiate the process, known
as metastasis. Their discovery of a new molecular mechanism by which MMP-9 promotes cancer spread may provide a new target
at which to aim anti-metastasis drugs. Jefferson Graduate and Medical Students Display Research at Sigma Xi Research Day March 21
Projects range from a potential way to stop colon cancer spread to how gene mutations affect skin structure in a rare blistering
disease
(Published 3-21-06) Some of the most sophisticated and advanced student research in science and medicine will be on display
at Thomas Jefferson University on Tuesday, March 21, 2006. The Jefferson chapter of Sigma Xi, the Scientific Research Society,
is holding its annual Student Research Day from 12:30 P.M. to 3 P.M. in Bluemle Life Sciences Building, 233 S. 10th Street.
ublished: 10-9-2006) Richard W. Haldeman, MBA, has joined the Kimmel Cancer Center (KCC) at Thomas Jefferson University in
Philadelphia as its new Chief Financial Officer (CFO). In this new position, Mr. Haldeman will financially integrate the research
and clinical functions of the organization. He will also serve as lead financial representative for KCC director Richard G.
Pestell, M.D., Ph.D., in both of his roles as Vice President of Oncology Services at Thomas Jefferson University Hospital
and Associate Dean for Cancer Programs at Thomas Jefferson University.
Featured in the Media
Colleges Make Own Medicine to Ease Research(Published 5-5-06, The Philadelphia Inquirer) Across the country, universities are beginning to manufacture drugs in their
own facilities. These universities offer lower-cost drugs and placebos, hoping to spark more “off-label” studies.
